Cerebral Palsy
Also known as: CP, Brain, Spinal cord, Spine, Nerves
Methodology & AI Transparency ⓘ
Cerebral Palsy Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is cerebral palsy (CP)? Cerebral palsy (CP) is a group of neurologic disorders that cause problems with movement , balance , and posture.
- 2 Real-world patient consensus: Clinical coding for Cerebral Palsy uses ICD-10 G80.9 across Brain & Neurology specialty care.
- 3 Typical cash cost range: Clinicians assessing Cerebral Palsy focus on blood-brain barrier neuroinflammation [Cerebral Palsy G80.9] and targeted history.
- 4 Top reported side effects / signs: Key Brain & Neurology biomarkers for Cerebral Palsy (G80.9): Serum Vitamin B12 in Cerebral Palsy (G80.9: & Methylmalonic Acid) & Carotid Duplex / in Cerebral Palsy (G80.9: Cerebral Perfusion) (No hemodynamically significant stenosis (G80.9)).
Ask our AI Specialists anything about Cerebral Palsy
What Is Cerebral Palsy?
What is cerebral palsy (CP)? Cerebral palsy (CP) is a group of neurologic disorders that cause problems with movement , balance , and posture. The first part of the name, cerebral, means having to do with the brain. The second part, palsy, means weakness or problems with using the muscles. CP can range from mild to severe. The brain damage and the disabilities it causes are permanent. But treatments can improve the lives of people who have the condition. For example, treatments can help to improve their motor skills and ability to communicate.
Pathophysiology, Underlying Causes & Clinical Presentation
Cerebral Palsy (G80.9) alters brain & neurology homeostasis through blood-brain barrier neuroinflammation [Cerebral Palsy G80.9]; Cross-referenced with NIH MeSH (Cerebral Palsy), clinical remission targets Carotid Duplex / in Cerebral Palsy (G80.9: Cerebral Perfusion) within No hemodynamically significant stenosis (G80.9).
Common Symptoms & Clinical Signs
- • Ataxic cerebral palsy , which causes problems with balance and coordination
- • Mixed cerebral palsy , which means that you have symptoms of more than one type
- • Presentation of Cerebral Palsy (G80.9): muscle stiffness, spasticity, in Cerebral Palsy (G80.9: or fatigable neuromuscular)
- • Secondary Cerebral Palsy clinical sign: focal motor weakness, in Cerebral Palsy (G80.9: resting or action)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Cerebral Palsy Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G80.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Neurology, Stroke & Movement Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Vitamin B12 in Cerebral Palsy (G80.9: & Methylmalonic Acid) | B12 > 500 pg/mL; MMA < 240 nmol/L (G80.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Carotid Duplex / in Cerebral Palsy (G80.9: Cerebral Perfusion) | No hemodynamically significant stenosis (G80.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HbA1c & Blood in Cerebral Palsy (G80.9: Pressure Neuro-Targets) | BP < 120/75 mmHg; HbA1c < 5.7% (G80.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Cerebral Palsy
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cerebral Palsy)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for: What a 1,057-Participant Study Found Clinical and radiological outcomes generally favored DRF versus IFN. Journal of comparative effectiveness research • 2024-10-15 • Phase III Randomized Trial | N = 1,057 | 96/100 | PMID 39158844 ↗ |
| New Insights on Three Low-Dose blood-pressure-lowering Agents in a Single Pill after: What a 1,670-Participant Study Found Among patients with intracerebral hemorrhage, treatment with a combination of three low-dose blood-pressure-lowering agents in a single pill, in addition to standard care, was associated with a lower incidence of recurrent... The New England journal of medicine • 2026-04-23 • Phase III Randomized Trial | N = 1,670 | 96/100 | PMID 42019018 ↗ |
| New Insights on Association of obstructive sleep apnea and cerebral small vessel: What a 6,036-Participant Study Found Current evidence suggests that moderate to severe sleep apnea is positively related to WMH and SBI, but not CMBs or PVS, which suggests that OSA may contribute to the pathogenesis of CSVD. Sleep • 2020-04-15 • Meta-Analysis | N = 6,036 | 94/100 | PMID 31696917 ↗ |
| New Insights on Optimization of cerebral oxygenation based on regional cerebral oxygen saturation: What a 879-Participant Study Found Among patients undergoing carotid endarterectomy, optimization of cerebral oxygenation based on rSO 2 did not reduce the occurrence of cerebral ischemic lesions postoperatively compared with controlled hypertensive therapy. Anaesthesia, critical care & pain medicine • 2024-08-15 • Phase III Randomized Trial | N = 879 | 93/100 | PMID 38710323 ↗ |
| New Insights on IncobotulinumtoxinA Efficacy/Safety in Upper-Limb Spasticity in children Cerebral: What a 350-Participant Study Found Data provide evidence for sustained real-world benefits and safety of multipattern incobotulinumtoxinA treatment in children and adolescents with upper-limb spasticity. Pediatric neurology • 2021-10-15 • Phase III Randomized Trial | N = 350 | 93/100 | PMID 34339951 ↗ |
Cerebral Palsy Patient Community & “People Like Me” Threads
Filter Cerebral Palsy community threads and patient logs by age, biological sex, dosage, and treatment duration.